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Neonatal fungal endocarditis is a rare but serious infection, which does not have a well-accepted management
method. This is the second report of this condition in Saudi Arabia. A preterm, very low birth weight, female neonate
presented with fever and shortness of breath. An echocardiogram showed moderate pericardial effusion and two
masses in the heart, one in the right ventricle and the other in the inferior portion of the posterior mitral valve of the left
ventricle. Blood and pericardial fluid cultures revealed an infection with Candida albicans. The patient received a
60 days course of intravenous fluconazole and amphotericin B lipid complex. At the conclusion of treatment, she was
discharged in good condition with no echocardiographic evidence of pericardial effusion or fungal vegetations. Thus, a
successful outcome to a serious case of fungal endocarditis was achieved through aggressive antifungal therapy with
intravenous fluconazole and amphotericin B lipid complex.
 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Keywords: Fungal endocarditis, Infective endocarditis, Candidemia, Candida albicans, Amphotericin B, FluconazoleAbbreviations: FE, fungal endocarditis, IE, infective endocarditis, NICU, neonatal intensive care unit, PICU, pediatric
intensive care unit, C. albicans, Candida albicans, CRP, C-reactive proteinCase report
A 14-day-old female patient presented to theKing Abdulaziz University Hospital Pediat-
ric Emergency facility with a high-grade fever,
progressive shortness of breath, and a dry cough.
The patient also had associated decreases in oral
intake and activity levels. The premature infant
was born at a gestational age of 32 weeks and
delivered by emergency cesarean section to a pri-
migravida mother who had been diagnosed with1016–7315  2012 King Saud University.
Production and hosting by Elsevier B.V. All rights reserved.
Peer review under responsibility of King Saud University.
URL: www.ksu.edu.sa
http://dx.doi.org/10.1016/j.jsha.2012.03.005severe pre-eclampsia. Born with a very low birth
weight of 1400 g, the infant was admitted to the
neonatal intensive care unit (NICU) for 10 days,
at a different hospital. During this period, she
did not require assisted ventilation, but did re-
ceive intravenous ampicillin and gentamicin for
5 days. The patient was discharged, against medi-
cal advice, due to the family’s financial situation.
The infant was asymptomatic for 2 days prior to
presentation.Production and hosting by Elsevier
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initial vital scores revealed a core temperature of
38.1 C (100.6 F), a heart rate of 168 beats per min-
ute, a respiratory rate of 76 per minute, blood
pressure of 90/55 mmHg, a mean arterial pressure
of 66 mmHg, and an oxygen saturation of 94%, on
room air. She was irritable and in moderate respi-
ratory distress, the first and second heart sounds
were normal, and a cardiac murmur was not
detected. A thorough physical examination did
not reveal any other abnormalities.
The patient was admitted to the pediatric medi-
cal ward with a provisional diagnosis of neonatal
sepsis. Intravenous fluids and broad-spectrum
intravenous antibiotics, ampicillin and cefotaxime,
were initiated following a full septic screen. Inves-
tigations revealed a total leukocytic count of
37  103 leukocytes/mm3, a hemoglobin level of
12.9 g/dL, and a platelet count of 215  103 plate-
lets/mm3. Urea, electrolytes, coagulation profile,
liver function tests, and blood gases were within
normal ranges. The patient’s C-reactive protein
(CRP) level was high, at 202 mg/L. A lumbar punc-
ture was performed and cerebrospinal fluid bio-
chemistry and cell counts were unremarkable.
Cerebrospinal fluid and urine were cultured on
test media, but microbiological growth was not de-
tected. Chest X-rays showed significant enlarge-Figure 1. Vegetative masses in the inferior portion of the left and right vement of the cardiac shadow with clear lung
fields. Two masses were revealed by echocardio-
gram, one was located in the left ventricle at-
tached to the posterior mitral valve, measuring
15  8 mm, and the other was in the trabecula-
tions of the right ventricle, measuring 10  6 mm
(Fig. 1). There was trivial mitral regurgitation
and moderate pericardial effusion with evidence
of a thickened pericardium.
The patient was shifted to the pediatric intensive
care unit (PICU) and furosemide and amphotericin
B were administered. Pericardiocentesis, under
echocardiographic guidance, was performed,
withdrawing 15 cc of clear fluid. Pericardial fluid
culture revealed multi-sensitive Candida albicans.
The pericardial cell count revealed a white blood
cell count of 18  103/lL and a red blood cell count
of 6150/lL. The patient’s blood culture was also
positive for C. albicans. Ampicillin and cefotaxime
were discontinued and were replaced with intra-
venous fluconazole (6 mg/kg/day) and amphoteri-
cin B lipid complex (10 mg/kg/day). Computed
tomography of the brain and ultrasonography of
the kidneys excluded any seeding in those organs.
After 4 days in the PICU, a follow-up echocardio-
gram was performed, which showed a decrease
in the pericardial effusion and in the size of the
masses.ntricles. The moderate size of the pericardial effusion is also evident.
Figure 2. Resolution of the vegetative masses following 8 weeks of treatment.
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medical ward. Three additional follow-up echo-
cardiograms were undertaken, approximately
10 days apart. These examinations all showed the
absence of pericardial effusion and decreasing
sizes of the vegetations. An echocardiogram, con-
ducted 42 days after the diagnosis, was devoid of
any abnormalities (Fig. 2), repeated blood cultures
were negative for C.albicans, the CRP level had de-
creased to 3.41 mg/L, and leukocytic count de-
creased to 9  103 leukocytes/mm3. Antifungal
therapy occurred over a total of 8 weeks.
The patient was discharged, after improving
clinically, and has had three follow-up echocar-
diograms, performed at 2, 12, and 22 weeks after
discharge. Over the course of these visits, there
has not been any clinical or echocardiographic
evidence of a recurrence; the discharge plan in-
cluded frequent follow-up visits to the clinic for
a minimum of 1 year after discharge.
The patient’ mother provided written informed
consent for the publication of this case report
and the accompanying images.Discussion
Infective endocarditis (IE) is a serious, but rela-
tively rare infection that is associated with a highdegree of morbidity and mortality. The disease
has an incidence of 0.8–3.3 per 1000 hospital
pediatric admissions [1]. Fungal endocarditis
(FE) is reported less frequently than bacterial
endocarditis, with an incidence, in children, of
0–12% of the total pediatric IE admissions. Over
the past few years, there has been an increasing
number of documented reports of IE and, more
particularly, FE [1–2]. The increased incidence of
FE is more evident among infants and is diag-
nosed in up to 20% of the IE cases in this popu-
lation [2–3]; over 60% of FE cases occur in infants
less than 1-year-old [1]. This is only the second
reported case in Saudi Arabia, which may sug-
gest that the disease is either under-reported or
misdiagnosed.
In neonates, FE rarely affects the native heart
valves and occurs most frequently as part of a dis-
seminated fungal infection. Risk factors for devel-
oping FE include a prolonged stay in the NICU,
prolonged use of intravenous antibiotics, cardiac
surgery, and the presence of an indwelling central
venous catheter. The most frequent complications
associated with FE are myocarditis, valve perfora-
tion, and sepsis with involvement of the brain and
kidneys. In neonates, both incidence and outcome
are negatively correlated to the gestational age
and the birth weight [4].
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agents of FE in infants (87%), with 42% of cases
resulting from C. albicans infection. In premature
infants, Candida spp. account for 64% of cases
and Aspergillus spp. account for 21% [1]. FE is often
difficult to diagnose, particularly in neonates, be-
cause the symptoms may be nonspecific, as seen
in this case report. The disease typically occurs
in otherwise critically ill patients and is often part
of a confusing clinical picture, with most patients
having difficulty meeting the Duke criteria for IE
[5].
In the present case, the diagnosis was made
within 2 days of the patient’s admission as a re-
sult, in part, of the availability of a pediatric cardi-
ology division within the facility.
Although a consensus approach for the appro-
priate management of FE in neonates is lacking, a
combined medical and surgical approach has been
used for treating infants who have ultimately sur-
vived candidal endocarditis. Several factors should
be considered in choosing the treatment modality;
these include the perioperative mortality (if surgi-
cal intervention is being considered), the severity
of the neonate’s illness, the side effects of the anti-
fungal, the hemodynamic status of the patient, and
the presence of any blood flow obstructions [3,6].
In the present case, surgical intervention to re-
move the vegetative masses was decided against
because the vegetations were not causing blood
flow obstructions or hemodynamic instability,
and the risk of perioperative mortality was high.
In addition, the likelihood of successful antifungal
chemotherapy was expected to be high since the
isolated species of fungus was sensitive to multiple
antifungal chemotherapeutics.
Numerous antifungal agents have been used in
open-label trials in neonates and children with
candidemia or invasive candidiasis. The most fre-
quently used treatment end-point in these trials
has been microbiologic clearance, which provided
another level of confidence in the decision to treat
the present case of FE with the chosen chemother-
apeutic agents. Among the antifungal agents used
to treat FE, amphotericin B and its lipid prepara-
tions, [7–8], azoles [9] and caspofungin [10] have
all been shown to have varying degrees of effec-
tiveness in neonates with candidal infections.
Clearance rates of 83–100% have been reported
for the lipid preparations of amphotericin B, 72–
97% for fluconazole, 81% for itraconazole,
85–100% for caspofungin, and 72% for micafungin
[10–11].
In the present case, recognition of the two car-
diac masses, which were more likely fungal ballsthan rhabdomyomas (based on the patient’s clini-
cal condition), amphotericin B was started imme-
diately, before the culture results were available.
After blood and pericardial fluid cultures revealed
C. albicans, amphotericin B was shifted to its lipid
form and fluconazole was added to the treatment
combination and administered for 8 weeks. Re-
peated blood cultures showed no evidence of fun-
gal infection 6 weeks after the initiation of the
antifungals. Amphotericin B lipid complex and
fluconazole were continued for an additional
2 weeks, as recommended by the Clinical Practice
Guidelines for the Management of Candidiasis
[12].Conclusions
FE in neonates is a rare, serious disease that has
a poor prognosis, if not treated properly. Interest-
ingly, this disease is encountered with increasing
frequency in today’s highly advanced medical
practices, globally. Recognizing FE early is chal-
lenging due to its nonspecific symptoms, but with
a high index of suspicion and understanding of
the predisposing factors, an accurate diagnosis
can be made. Management with antifungal medi-
cations can be an adequate choice, even in criti-
cally ill patients.Disclosure
The author does not have any competing
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